Inogen

Inogen, Inc. engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its products include Inogen One G4 system, Inogen One G3 system, Inogen One G5 system, Inogen TAV, and Inogen at Home. The company was founded by Alison Perry, Alison K. Bauerlein, Brenton Taylor, and Byron Myers on November 27, 2001 and is headquartered in Goleta, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inogen reports revenue growth amidst challenges, eyes positive EBITDA

Inogen reported revenue growth in Q4 2022 despite challenges and aims for positive adjusted EBITDA by Q4 2023. The company successfully managed supply chain challenges and plans new product launches in 2023.
While facing challenges in DTC evolution and gross margin decline, Inogen sees promising market opportunities for sustainable growth. The company's strategic decisions to secure supply assurance and focus on innovation position it for future success.
With a focus on addressing challenges, leveraging strengths, and capitalizing on opportunities, Inogen is poised for growth and profitability in 2023. The company's commitment to managing disruptions and driving commercial strategy reflects a positive outlook for the future.

Inogen reports Q1 performance meeting expectations, eyes profitability by Q4

Inogen's Q1 2023 performance was mixed, with revenue meeting expectations but facing challenges in certain sales segments.
The company's strategic focus on patient-centric models and product expansion positions it well for future growth.
With a clear roadmap to profitability by Q4 2023 and a strong financial position, Inogen remains optimistic about its outlook.

Inogen reports Q2 revenue shortfall, focuses on strategic growth

Inogen faced challenges in Q2 2023 but is focused on strategic initiatives to drive growth and regain lost business.
The company's financial results were impacted by supply chain constraints, aggressive pricing tactics, and restructuring charges.
Opportunities for growth exist through international expansion, product enhancements, and entering new market segments.
Management's emphasis on commercial execution and innovation highlights a commitment to sustainable growth.

Inogen reports Q3 revenue decline, eyes international growth opportunities

Inogen faced revenue declines in Q3 2023, driven by challenges in direct-to-consumer and domestic B2B sales.
Despite these setbacks, the company showed strength in international B2B and rental revenue growth.
Operational efficiency improvements and strategic cost controls are crucial for addressing margin pressures and financial performance.
The acquisition of Physio-Assist underscores Inogen's commitment to expanding its product portfolio and enhancing market competitiveness.

Inogen reports $316M full-year revenue, eyes growth amid challenges

Inogen's Q4 2023 earnings call highlighted achievements, challenges, and opportunities. The company aims to drive growth through strategic priorities, innovation, and market leadership. Despite facing challenges in revenue and net loss, Inogen is focused on improving performance and capitalizing on market opportunities.

Inogen reports solid Q1 earnings, eyes growth amid market challenges

Inogen's Q1 2024 performance reflects steady revenue growth, improved gross margins, and prudent cost management. The company's strategic priorities, strong financial position, and revenue guidance for Q2 2024 signal resilience and growth potential amidst market challenges and opportunities.

Inogen reports Q2 revenue growth and profitability amidst operational challenges

Inogen's Q2 2024 performance showed revenue growth, improved gross margin, and achieved adjusted EBITDA profitability.
While facing challenges like increased operating expenses and DTC sales decline, the company is focused on sustainable profitability.
Opportunities lie in channel-specific strategies, innovation pipeline expansion, and long-term growth investments.

Inogen reports $89M Q3 revenue with improved profitability and strategic growth

Inogen delivered solid Q3 performance with revenue growth and profitability. Faces challenges in direct-to-consumer sales and net loss. Opportunities lie in improving sales force efficiency and expanding market reach. Strong financial position for future growth initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inogen, Inc. is a medical technology company, which engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its products include Inogen One G4 system, Inogen One G3 system, Inogen One G5 system, Inogen TAV, and Inogen at Home. The company was founded by Alison Perry, Alison K. Bauerlein, Brenton Taylor, and Byron Myers on November 27, 2001 and is headquartered in Goleta, CA.

Inogen, Inc. (NASDAQ:INGN ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Agnes Lee - SVP of IR and Strategic Planning Nabil Shabshab - President and CEO Kristin Caltrider - CFO Conference Call Participants Brett Fishbin - KeyBanc Maggie Boeye - William Blair Rohin Patel - JPMorgan Mike Matson - Needham & Company Operator Welcome to the Inogen's Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Inogen, Inc. (INGN) CEO Nabil Shabshab on Q2 2022 Results - Earnings Call Transcript

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended June 30, 2022 and provided a business update. Second Quarter 2022 Highlights Reported total revenue was $103.4 million for the period ended June 30, 2022, representing a 1.8% increase from $101.6 million for the period ended June 30, 2021. On a constant currency basis, total re

Inogen Announces Second Quarter 2022 Financial Results

Inogen (INGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Inogen (INGN) Surges 5.1%: Is This an Indication of Further Gains?

Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Inogen (INGN) Q2 Earnings Expected to Decline

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release second quarter 2022 financial results after market close on Thursday, August 4, 2022. The Company will host a corresponding conference call beginning at 2:00 pm PT/5:00 pm ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Internation

Inogen to Announce Second Quarter 2022 Financial Results on August 4, 2022

Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.

Here's Why You Should Hold on to Inogen (INGN) Stock For Now

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Agnes Lee to the position of Senior Vice President of Investor Relations and Strategic Planning, effective May 23, 2022. Nabil Shabshab, President and Chief Executive Officer, said, “I am excited to welcome Agnes to the Inogen team as we continue to strengthen our strategic planning capabilities, f

Inogen Names Agnes Lee as Senior Vice President of Investor Relations and Strategic Planning

Inogen's (INGN) first-quarter results benefit from higher revenues across the majority of its geographical segments and categories.

Inogen (INGN) Stock Inches Up 0.5% Post Q1 Earnings Beat

Inogen, Inc. (NASDAQ:INGN ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Jason Somer - General Counsel Nabil Shabshab - President & CEO Kristin Caltrider - CFO Conference Call Participants Lilia-Celine Lozada - J.P. Morgan Matthew Mishan - KeyBanc Capital Markets Mike Matson - Needham & Company Operator Welcome to Inogen's First Quarter 2022 Earnings Conference Call.

Inogen's (INGN) CEO Nabil Shabshab on Q1 2022 Results - Earnings Call Transcript

Inogen (INGN) delivered earnings and revenue surprises of 20.83% and 5.09%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Inogen (INGN) Reports Q1 Loss, Tops Revenue Estimates

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three months ended March 31, 2022. First Quarter 2022 Highlights Total revenue of $80.4 million, down 7.5% from the same period in 2021, primarily due to supply chain constraints Total revenue up 5.2% sequentially from the fourth quarter of 2021 Domestic direct-to-consumer revenue of $34.4 mi

Inogen Announces First Quarter 2022 Financial Results

VISTA, Calif.--(BUSINESS WIRE)--Sommetrics, a private company developing products and services to improve sleep health, today released an update on its key accomplishments during the first quarter of 2022. Chief among these accomplishments was the Company's advancing clinical activities aimed at obtaining FDA market clearance for its flagship product, aerSleep® II, that is targeted for the treatment of obstructive sleep apnea in those unable to use standard therapy with continuous positive airw

Sommetrics Provides Update on the Pivotal SUPRA Clinical Trial for Sleep Apnea and Recent Corporate Accomplishments

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release first quarter 2022 financial results after market close on Thursday, May 5, 2022. The Company will host a corresponding conference call beginning at 2:00pm PT/5:00pm ET. Individuals interested in listening to the conference call may do so by dialing (877) 841-3961 for domestic callers or (201) 689-8589

Inogen to Announce First Quarter 2022 Financial Results on May 5, 2022

Supply chain issues have hit Inogen hard, undermining the company's ability to ship to demand and driving some share loss despite healthy underlying demand trends.

Hammered By Supply Issues, Inogen Could Be A 2023 Comeback Story

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the Company's management will be participating in the 21st Annual Needham Virtual Healthcare Conference. Inogen's President and CEO, Nabil Shabshab, and CFO, Kristin Caltrider, are scheduled to present on Wednesday, April 13th, 2021 at 12:45 p.m. ET. Interested parties can access the webcast from the News / Even

Inogen Announces Participation in the 21st Annual Needham Virtual Healthcare Conference

Inogen (INGN) continues to benefit from strength in the direct-to-customer business model. However, rising costs remain a woe.

Here's Why You Should Hold on to Inogen (INGN) Stock Now

GOLETA, California--(BUSINESS WIRE)--Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Glenn Boehnlein, Kevin King, and Mary Katherine Ladone to Inogen's Board of Directors, effective March 22, 2022. In conjunction with these appointments, Heath Lukatch (director since 2006), Benjamin Anderson-Ray (director since 2013), and Loren McFarland (director since 2013) retired from the B

Inogen Announces Board of Director Changes

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the Company's management will be participating in the KeyBanc Life Sciences & MedTech Investor Forum. Inogen's President and CEO, Nabil Shabshab, and CFO, Kristin Caltrider, are scheduled to present on Wednesday, March 23rd, 2022 at 4:30 p.m. ET. Interested parties can access the webcast from the News / Even

Inogen Announces Participation in the KeyBanc Life Sciences & MedTech Investor Forum

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Kristin Caltrider as EVP & Chief Financial Officer, effective March 21, 2022. Ms. Caltrider succeeds Mike Sergesketter, who joined the Company as interim CFO in December 2021, and will remain with Inogen through June 24, 2022 to facilitate a smooth transition. Nabil Shabshab, President and Chie

Inogen Names Kristin Caltrider as Chief Financial Officer

Inogen's (INGN) fourth-quarter results benefit from higher revenues across the majority of its geographical segments.

Inogen (INGN) Stock Surges 16.5% Despite Q4 Earnings Miss

Inogen, Inc. (INGN) CEO Nabil Shabshab on Q4 2021 Results - Earnings Call Transcript

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three- and twelve-month periods ended December 31, 2021. Fourth Quarter 2021 Highlights Total revenue of $76.4 million, up 3.3% from the same period in 2020, in line with the mid-point of its preliminary, unaudited revenue estimate provided on January 10, 2022 Domestic direct-to-consumer reve

Inogen Announces Fourth Quarter and Full Year 2021 Financial Results

Inogen (INGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Inogen (INGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release fourth quarter 2021 financial results after market close on Thursday, February 24, 2022. The Company will host a corresponding conference call beginning at 2:00pm PT/5:00pm ET. Individuals interested in listening to the conference call may do so by dialing (877) 841-3961 for domestic callers or (201) 6

Inogen to Announce Fourth Quarter 2021 Financial Results on February 24, 2022

Inogen's (INGN) revenue growth in the fourth quarter is likely to have been boosted by solid product sales despite supply chain constraints.

News for Inogen Stock (INGN)